Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Summary of Significant Accounting Policies (Policies)
Notes Tables
Notes Details

Subsequent Events (Narrative) (Details)

v3.21.2

Subsequent Events (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands				3 Months Ended	9 Months Ended
	Nov. 16, 2021	Nov. 12, 2021	Oct. 05, 2021	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Subsequent Event [Line Items]
Stock offering, aggregate fees paid					$ 85	$ 1,506
Caelum [Member]
Subsequent Event [Line Items]
Fair value of investment				$ 17,600	17,600		$ 17,600
Increase in fair value of investments					$ 39,294
Avenue [Member] \| IPO [Member] \| Scenario, Plan [Member]
Subsequent Event [Line Items]
Stock offering, number of shares issued	3,520,000
Stock offering, price per share	$ 10.00
Sale of stock, net proceeds	$ 31,400
Avenue [Member] \| Over-Allotment Option [Member] \| Scenario, Plan [Member]
Subsequent Event [Line Items]
Stock offering, number of shares issued	528,000
AstraZeneca [Member] \| Caelum [Member]
Subsequent Event [Line Items]
Percentage of escrow holdback					10.00%
Fair value of investment				56,900	$ 56,900
Increase in fair value of investments				$ 8,400	$ 39,300
Subsequent Events [Member] \| Journey [Member] \| IPO [Member]
Subsequent Event [Line Items]
Stock offering, price per share	$ 10.00
Subsequent Events [Member] \| Avenue [Member] \| Over-Allotment Option [Member]
Subsequent Event [Line Items]
Stock offering, gross proceeds		$ 3,000
Subsequent Events [Member] \| Avenue [Member] \| Public Offering [Member]
Subsequent Event [Line Items]
Stock offering, number of shares issued		1,946,787
Stock offering, gross proceeds		$ 2,600
Stock offering, price per share		$ 1.34
Option to purchase additional number of shares, percentage of total shares		15.00%
Subsequent Events [Member] \| AstraZeneca [Member] \| Caelum [Member]
Subsequent Event [Line Items]
Percentage of proceeds from option exercise			42.40%
Option exercise price			$ 150,000
Proceeds from option exercise			$ 56,900
Percentage of escrow holdback			10.00%

- Definition

Amount of investment for option to purchase equity.

+ References

No definition available.

+ Details

Name:	fbio_DeconsolidationOfConsolidatedPartnerCompanyOptionExercisePrice
Namespace Prefix:	fbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Deconsolidation of consolidated partner company, percentage of the proceeds received for distribution of option to purchase equity.

+ References

No definition available.

+ Details

Name:	fbio_DeconsolidationOfConsolidatedPartnerCompanyPercentageOfNetProceedsReceiveUponDistributionOfOptionExercisePrice
Namespace Prefix:	fbio_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of proceeds from exercise of option to purchase equity.

+ References

No definition available.

+ Details

Name:	fbio_DeconsolidationOfConsolidatedPartnerCompanyProceedsReceivedFromOptionExercise
Namespace Prefix:	fbio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Deconsolidation of partner company, percentage of escrow holdback.

+ References

No definition available.

+ Details

Name:	fbio_DeconsolidationOfPartnerCompanyPercentageOfEscrowHoldback
Namespace Prefix:	fbio_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Option to purchase additional number of shares, percentage of total shares.

+ References

No definition available.

+ Details

Name:	fbio_OptionToPurchaseAdditionalNumberOfSharesPercentageOfTotalShares
Namespace Prefix:	fbio_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

+ Details

Name:	us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

+ Details

Name:	us-gaap_InvestmentsFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The cash outflow for cost incurred directly with the issuance of an equity security.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585

+ Details

Name:	us-gaap_PaymentsOfStockIssuanceCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Cash received on stock transaction after deduction of issuance costs.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockConsiderationReceivedPerTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockPricePerShare
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

+ References

No definition available.

+ Details

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_ConsolidatedEntitiesAxis=fbio_CaelumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ConsolidatedEntitiesAxis=fbio_AvenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=fbio_AstrazenecaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ConsolidatedEntitiesAxis=fbio_JourneyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=fbio_PublicOfferingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: